Correlation Between Hansa Biopharma and Vicore Pharma

Can any of the company-specific risk be diversified away by investing in both Hansa Biopharma and Vicore Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Hansa Biopharma and Vicore Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Hansa Biopharma AB and Vicore Pharma Holding, you can compare the effects of market volatilities on Hansa Biopharma and Vicore Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Hansa Biopharma with a short position of Vicore Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Hansa Biopharma and Vicore Pharma.

Diversification Opportunities for Hansa Biopharma and Vicore Pharma

0.33

Correlation Coefficient

Hansa Biopharma  Vicore Pharma

Weak diversification

The 3 months correlation between Hansa and Vicore is 0.33. Overlapping area represents the amount of risk that can be diversified away by holding Hansa Biopharma AB and Vicore Pharma Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Vicore Pharma Holding and Hansa Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Hansa Biopharma AB are associated (or correlated) with Vicore Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Vicore Pharma Holding has no effect on the direction of Hansa Biopharma i.e., Hansa Biopharma and Vicore Pharma go up and down completely randomly.

Pair Corralation between Hansa Biopharma and Vicore Pharma

Assuming the 90 days trading horizon Hansa Biopharma is expected to generate 1.21 times less return on investment than Vicore Pharma. In addition to that, Hansa Biopharma is 1.18 times more volatile than Vicore Pharma Holding. It trades about 0.08 of its total potential returns per unit of risk. Vicore Pharma Holding is currently generating about 0.11 per unit of volatility. If you would invest  633.00  in Vicore Pharma Holding on April 22, 2025 and sell it today you would earn a total of  147.00  from holding Vicore Pharma Holding or generate 23.22% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	98.39%
Values	Daily Returns

Hansa Biopharma AB  vs.  Vicore Pharma Holding

Hansa Biopharma AB

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Hansa Biopharma AB are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Hansa Biopharma unveiled solid returns over the last few months and may actually be approaching a breakup point.

Vicore Pharma Holding

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Vicore Pharma Holding are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Vicore Pharma unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Hansa Biopharma and Vicore Pharma

The main advantage of trading using opposite Hansa Biopharma and Vicore Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Hansa Biopharma position performs unexpectedly, Vicore Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vicore Pharma will offset losses from the drop in Vicore Pharma's long position.

The idea behind Hansa Biopharma AB and Vicore Pharma Holding pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.